Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Liabilities and Shareholders Equity (2016 - 2018)

Armata Pharmaceuticals' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $10.6 million for Q3 2018.

  • For Q3 2018, Liabilities and Shareholders Equity fell 22.94% year-over-year to $10.6 million; the TTM value through Dec 2018 reached $36.7 million, down 32.38%, while the annual FY2017 figure was $11.1 million, 38.64% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2018 was $10.6 million at Armata Pharmaceuticals, down from $11.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $38.6 million in Q1 2015 and bottomed at $10.6 million in Q3 2018.
  • The 5-year median for Liabilities and Shareholders Equity is $27.1 million (2016), against an average of $24.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity increased 6.73% in 2015 before it plummeted 49.39% in 2017.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $28.6 million in 2014, then increased by 19.08% to $34.1 million in 2015, then crashed by 46.73% to $18.2 million in 2016, then tumbled by 38.64% to $11.1 million in 2017, then decreased by 4.66% to $10.6 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's Liabilities and Shareholders Equity are $10.6 million (Q3 2018), $11.7 million (Q2 2018), and $14.4 million (Q1 2018).